Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
BURLINGTON, Mass., Feb. 28, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Florida. Dr. Clayman is scheduled to present at 8:05 a.m Eastern Time on Tuesday, March 6, 2018. Investors can access the live webcast and subsequent archived recording of the presentation by visiting the Flexion website at http://ir.flexiontherapeutics.com
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of The Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.
Corporate Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
